FogPharma

FogPharma, headquartered at Cambridge Discovery Park in Cambridge, MA, is a clinical-stage company pioneering a new class of drugs aimed at overcoming the limitations of current precision medicines to achieve universal druggability. The company’s discovery engine integrates cutting-edge technologies to dramatically accelerate the speed and scalability of drug discovery. FogPharma’s Helicons combine the targeting strength and specificity of antibodies with the broad tissue distribution and intracellular target engagement of small molecules. The company’s lead program, FOG-001, is a first-in-class TCF-blocking β-catenin inhibitor currently being evaluated in a Phase 1/2 clinical trial. FogPharma has announced collaborations with ARTBIO to co-develop Helicon-enabled alpha radioligand therapies for cancer treatment and has secured significant financing rounds, including $145 million to support ongoing clinical development of FOG-001 and $178 million in Series D financing to advance its pipeline of Helicon polypeptide therapeutics. The company was named a “Fierce 15” Biotech Company of 2023 by Fierce Biotech. FogPharma’s pipeline includes programs targeting ERG in prostate cancers, Cyclin E1/2 in amplified and overexpressed tumor types, and gain-of-function mutations in the RAS family of oncogenes, which are implicated in approximately 25% of human cancers. The company’s technology centers on constraining short chains of amino acids into an α-helical conformation, conferring unique drug-like properties, and aims to dramatically accelerate drug discovery compared to standard processes.